Diadema Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Diadema Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.4M	Buy	+54,755	New	+$9.57M	1.76%	18
2025 Q4	–	Sell	-23,140	Closed	-$3.55M	–	166
2025 Q3	$3.05M	Sell	23,140 -81,333	-78%	-$9.76M	0.78%	44
2025 Q2	$11.1M	Buy	104,473 +17,284	+20%	+$1.88M	3.38%	8
2025 Q1	$10.8M	Buy	87,189 +72,470	+492%	+$9.45M	2.82%	11
2024 Q4	$1.81M	Buy	+14,719	New	+$1.73M	0.78%	39

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Diadema Partners's JAZZ Position: Q1 2026 in Review

Diadema Partners opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 54,755 shares worth $10.4M. The stake represents 1.76% of the portfolio and ranks #18 among its holdings. This is a return to the name: Diadema Partners previously reported a position in JAZZ as recently as Q3 2025.

Diadema Partners first reported a position in JAZZ in Q4 2024 and has held it in 5 quarters since. The position peaked at $11.1M in Q2 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Diadema Partners held 54,755 shares of Jazz Pharmaceuticals worth $10.4M as of Q1 2026.
Jazz Pharmaceuticals was a new Diadema Partners position in Q1 2026.
Jazz Pharmaceuticals made up 1.76% of Diadema Partners's portfolio in Q1 2026, its #18 holding.
Diadema Partners first reported a position in Jazz Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
Diadema Partners's Jazz Pharmaceuticals position peaked at $11.1M in Q2 2025.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.